Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Flagship launches Ring with $50M, new gene therapy vectors

Ring aims to solve gene therapy’s biggest problems: immunogenicity, tissue access and genomic integration

Lauren Martz, Associate Editor
December 19, 2019 1:04 PM UTC
Updated on Dec 19, 2019 at 4:59 PM UTC

Ring Therapeutics, the latest company to emerge from Flagship Pioneering, has a gene therapy platform that it thinks will solve the biggest problems with the modality: immunogenicity, tissue access and genomic integration.

With a $50 million initial investment, the company is creating a new type of viral vector based on a family of commensal human viruses dubbed anelloviruses, which naturally exist in most of the human population without any apparent health impacts...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ring Therapeutics Inc.